Brilax

Brilax

Sodium Picosulfate

As a laxative in the following cases:

constipation caused by atony and hypotension of the colon (including in the elderly, in bedridden patients, after surgery, after childbirth and during lactation),

constipation caused by taking drugs,

regulation of stool for hemorrhoids, proctitis, anal fissures (to soften the consistency of feces),

diseases of the gallbladder, irritable bowel syndrome with a predominance of constipation,

constipation caused by intestinal dysbiosis, dietary disorders.

Inside. To obtain a laxative effect in the morning, you should take the drug the day before at night.

The following dosage regimen is recommended: adults and children over 10 years — 10-20 drops/day (5-10 mg/day), children 4-10 years — 5-10 drops/day (2.5-5 mg/day), under 4 years-0.25 mg / kg/day (this corresponds to 1 drop of the drug (0.5 mg of sodium picosulfate)/2 kg/day).

It is recommended to start with the lowest dose. In order to achieve regular stools, the dose may be increased to the maximum recommended dose. Do not exceed the maximum recommended daily dose.

The drug does not have to be dissolved in liquid.

hypersensitivity to sodium picosulfate or other components of the drug,

intestinal obstruction or obstructive bowel disease,

acute diseases of the abdominal organs, including appendicitis, or severe abdominal pain, which may be accompanied by nausea, vomiting, and fever,

acute inflammatory bowel diseases,

severe dehydration,

fructose intolerance.

From the gastrointestinal tract: discomfort, nausea, vomiting, abdominal cramps and pain, diarrhea.

From the nervous system: dizziness and fainting that occur after taking the drug may be associated with a vasovagal reaction (for example, tension during defecation, abdominal cramps).

On the part of the immune system: hypersensitivity reactions.

From the skin and subcutaneous tissues: skin reactions (for example, angioedema, skin rash, drug rash, itching).

Symptoms: when taking high doses, diarrhea, dehydration, a decrease in blood pressure, a violation of the water-electrolyte balance, hypokalemia, convulsions are possible. In addition, there are reports of cases of ischemia of the musculature of the large intestine associated with taking doses of the drug Brilax^® significantly higher than recommended for the usual treatment of constipation.

Brilax^® like other laxatives, chronic overdose can lead to chronic diarrhea, abdominal pain, hypokalemia, secondary hyperaldosteronism, and urolithiasis. Due to chronic laxative abuse, damage to the renal tubules, metabolic alkalosis, and muscle weakness associated with hypokalemia may develop.

Treatment: to reduce the absorption of the drug after oral administration — induction of vomiting or gastric lavage. It may be necessary to replenish the fluid and correct the balance of electrolytes, as well as the appointment of antispasmodics.

The active substance-sodium picosulfate-is a laxative of the triarylmethane group. As a local laxative, sodium picosulfate, after bacterial cleavage in the large intestine, has a stimulating effect on the mucosa of the large intestine, increasing peristalsis, promotes the accumulation of water and electrolytes in the large intestine. This leads to the stimulation of the act of defecation, a reduction in the evacuation time and a softening of the stool.

Sodium picosulfate, being a laxative that acts at the level of the large intestine, stimulates the natural process of evacuation of the contents from the lower gastrointestinal tract. Therefore, sodium picosulfate has no effect on the digestion or absorption of high-calorie foods or essential nutrients in the small intestine.

The absorption is insignificant, the drug is almost completely metabolized in the intestinal wall and liver to inactive glucuronide.

After oral administration of sodium picosulfate enters the large intestine, the absorption of the drug is insignificant, which excludes its enterohepatic circulation. In the distal part of the large intestine, sodium picosulfate is broken down to form the active metabolite, bis - (p-hydroxyphenyl)- pyridyl-2-methane. The time of development of the laxative effect of the drug is determined by the rate of release of the active metabolite and is usually 6-12 hours after application (on average 10 hours).

A small part of the drug enters the systemic circulation. There is no correlation between the laxative effect of the active metabolite and its concentration in the blood serum.

After taking 10 mg of the drug inside, about 10.4% of the total dose is excreted by the kidneys in the form of glucuronide after 48 hours.

When using higher doses of the drug, its excretion by the kidneys, in general, decreases.

• Laxative [Laxatives]

Diuretics or corticosteroids increase the risk of electrolyte imbalance (hypokalemia) when taking high doses of Brilax^®.

Electrolyte imbalance may increase sensitivity to cardiac glycosides.

The combined use of the drug and antibiotics may reduce the laxative effect of the drug.